Skip to main content
. 2022 Feb 22;13:828319. doi: 10.3389/fimmu.2022.828319

Figure 6.

Figure 6

TIGIT blockade antibody shows potent efficacy and combination activity with PD-1 antibody in mouse models. (A) murine TIGIT blockade antibody mu10A7 with indicated Fc was administered to CT26.WT tumor-bearing mice (5 mg/kg, QW). N = 13. (B) CT26.WT tumor-bearing humanized TIGIT knock-in mice were treated with indicated antibodies (10 mg/kg, Q5D), N = 10. (C) MC38 tumor-bearing humanized TIGIT knock-in mice were treated with vehicle (DPBS), Ch15mt (1 mg/kg, Q5D), BGB-A1217 (3 mg/kg, Q5D) or the combination; N = 10. (D) Renca tumor-bearing mice were treated with murine TIGIT blockade antibody mu10A7 (5 mg/kg, QW), murine PD-1 blockade antibody Ch15mt (3 mg/kg, QW), or the combination as indicated. N = 15; Data shown as mean ± SEM. Comparison between each treatment and the vehicle group on the last day was performed using one-way ANOVA with Dunnett multiplicity adjustment (A, B). Comparison between the combination treatment and each single agent treatment on the last day was performed using Tobit model (C, D). ns, no significant difference.